See more : Shiseido Company, Limited (4911.T) Income Statement Analysis – Financial Results
Complete financial analysis of ImmuCell Corporation (ICCC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmuCell Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Qomolangma Acquisition Corp. (QOMOR) Income Statement Analysis – Financial Results
- BHP Group Limited (BHP) Income Statement Analysis – Financial Results
- Antioquia Gold Inc. (AGDXF) Income Statement Analysis – Financial Results
- Accelleron Industries AG (ACLIF) Income Statement Analysis – Financial Results
- Hilton Worldwide Holdings Inc. (HLT) Income Statement Analysis – Financial Results
ImmuCell Corporation (ICCC)
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.47M | 18.57M | 19.24M | 15.34M | 13.72M | 10.99M | 10.43M | 9.54M | 10.23M | 7.60M | 6.01M | 5.39M | 5.11M | 4.39M | 4.51M | 4.63M | 6.07M | 4.80M | 4.98M | 3.70M | 3.36M | 6.18M | 6.68M | 5.64M | 4.91M | 4.50M | 4.60M | 4.40M | 4.90M | 4.40M | 3.90M | 3.10M | 2.20M | 3.00M | 2.80M |
| Cost of Revenue | 13.08M | 10.92M | 10.59M | 8.48M | 6.98M | 5.79M | 5.21M | 4.12M | 3.98M | 3.15M | 2.95M | 2.34M | 2.30M | 2.08M | 2.11M | 2.56M | 2.27M | 1.88M | 1.63M | 1.45M | 1.35M | 2.80M | 3.22M | 2.67M | 2.05M | 1.90M | 1.70M | 1.80M | 1.80M | 1.80M | 1.70M | 1.40M | 1.30M | 1.10M | 1.50M |
| Gross Profit | 4.40M | 7.65M | 8.66M | 6.86M | 6.74M | 5.19M | 5.22M | 5.42M | 6.25M | 4.45M | 3.06M | 3.05M | 2.81M | 2.30M | 2.40M | 2.07M | 3.80M | 2.92M | 3.35M | 2.25M | 2.01M | 3.39M | 3.46M | 2.97M | 2.86M | 2.60M | 2.90M | 2.60M | 3.10M | 2.60M | 2.20M | 1.70M | 900.00K | 1.90M | 1.30M |
| Gross Profit Ratio | 25.16% | 41.19% | 44.98% | 44.73% | 49.11% | 47.28% | 50.05% | 56.80% | 61.11% | 58.56% | 50.95% | 56.67% | 55.05% | 52.49% | 53.25% | 44.77% | 62.62% | 60.79% | 67.21% | 60.80% | 59.87% | 54.74% | 51.85% | 52.66% | 58.21% | 57.78% | 63.04% | 59.09% | 63.27% | 59.09% | 56.41% | 54.84% | 40.91% | 63.33% | 46.43% |
| Research & Development | 4.39M | 4.49M | 4.17M | 4.35M | 3.69M | 3.52M | 2.05M | 1.24M | 1.24M | 2.18M | 1.15M | 917.60K | 1.72M | 1.49M | 1.64M | 1.75M | 1.58M | 965.93K | 1.27M | 1.09M | 1.35M | 1.05M | 849.00K | 922.35K | 812.89K | 1.00M | 1.10M | 1.30M | 1.50M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.13M | 2.26M | 1.73M | 1.72M | 1.69M | 1.74M | 1.52M | 1.45M | 1.29M | 1.16M | 939.19K | 918.44K | 856.61K | 849.06K | 872.53K | 926.29K | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.09M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 1.83M | 1.61M | 1.32M | 986.77K | 973.22K | 869.87K | 650.89K | 410.74K | 569.71K | 0.00 | 401.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.22M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 3.29M | 2.89M | 2.48M | 1.93M | 1.89M | 1.73M | 1.50M | 1.28M | 1.50M | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 1.30M | 2.20M | 1.90M | 2.20M | 2.30M | 2.10M |
| Other Expenses | 0.00 | -187.00K | -326.00K | 348.00K | -314.00K | -413.00K | -195.00K | -24.85K | 5.64K | -3.90K | 31.90K | 8.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Operating Expenses | 9.62M | 9.95M | 8.40M | 8.24M | 7.69M | 7.34M | 5.46M | 4.53M | 4.13M | 4.66M | 3.08M | 2.81M | 3.45M | 2.99M | 2.93M | 3.24M | 2.93M | 2.15M | 2.41M | 2.13M | 2.44M | 2.85M | 2.79M | 2.55M | 2.24M | 2.60M | 2.60M | 2.70M | 3.10M | 2.90M | 2.30M | 2.00M | 2.30M | 2.40M | 2.20M |
| Cost & Expenses | 23.22M | 20.87M | 18.99M | 16.72M | 14.68M | 13.13M | 10.67M | 8.65M | 8.11M | 7.80M | 6.03M | 5.14M | 5.74M | 5.08M | 5.04M | 5.80M | 5.20M | 4.03M | 4.05M | 3.58M | 3.79M | 5.65M | 6.01M | 5.22M | 4.29M | 4.50M | 4.30M | 4.50M | 4.90M | 4.70M | 4.00M | 3.40M | 3.60M | 3.50M | 3.70M |
| Interest Income | 0.00 | 153.10K | 18.81K | 27.44K | 118.28K | 14.30K | 16.91K | 54.66K | 19.17K | 15.55K | 12.49K | 17.20K | 15.00K | 26.00K | 96.29K | 204.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 340.88K | 314.36K | 412.69K | 431.79K | 427.78K | 218.57K | 161.70K | 80.24K | 57.83K | 66.69K | 75.27K | 81.00K | 22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.72M | 2.49M | 2.47M | 2.36M | 2.27M | 1.52M | 904.44K | 802.38K | 529.26K | 448.92K | 417.20K | 402.52K | 418.37K | 419.51K | 424.44K | 399.10K | 788.90K | 278.52K | 643.62K | 278.52K | 256.27K | 236.77K | 177.00K | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| EBITDA | -2.50M | 349.99K | 2.72M | 1.65M | 1.43M | 88.44K | 684.53K | 1.72M | 2.65M | 251.30K | 692.04K | 672.82K | -192.31K | -241.90K | -4.07K | -768.49K | 1.66M | 1.05M | 1.58M | 399.29K | -172.76K | 769.91K | 847.61K | 546.53K | 716.51K | 100.00K | 400.00K | 0.00 | 200.00K | -100.00K | 0.00 | -200.00K | -1.30M | -400.00K | -800.00K |
| EBITDA Ratio | -14.33% | -12.38% | 1.34% | -8.99% | -6.95% | -25.91% | -2.33% | 18.05% | 26.13% | 3.31% | 7.31% | 12.43% | -3.90% | -5.58% | -2.32% | -16.64% | 27.45% | 21.95% | 31.63% | 10.80% | -37.89% | -2.68% | 8.48% | 9.70% | 16.57% | 2.22% | 8.70% | 2.27% | 4.08% | -4.55% | 0.00% | -6.45% | -59.09% | -13.33% | -28.57% |
| Operating Income | -5.75M | -2.30M | -2.20M | -1.38M | -954.00K | -1.45M | -243.00K | 890.20K | 2.12M | -206.40K | -19.55K | 245.00K | -632.73K | -690.28K | -527.03K | -1.17M | 872.10K | 770.68K | 938.03K | 120.77K | -429.03K | 533.14K | 671.00K | 413.37K | 614.97K | 0.00 | 300.00K | -100.00K | 0.00 | -300.00K | -100.00K | -300.00K | -1.40M | -500.00K | -900.00K |
| Operating Income Ratio | -32.90% | -12.38% | -11.45% | -8.99% | -6.95% | -13.17% | -2.33% | 9.33% | 20.75% | -2.72% | -0.33% | 4.55% | -12.38% | -15.74% | -11.69% | -25.20% | 14.37% | 16.05% | 18.82% | 3.27% | -12.78% | 8.62% | 10.05% | 7.33% | 12.53% | 0.00% | 6.52% | -2.27% | 0.00% | -6.82% | -2.56% | -9.68% | -63.64% | -16.67% | -32.14% |
| Total Other Income/Expenses | -21.89K | -187.19K | -326.51K | 348.10K | -313.51K | -413.48K | -195.64K | -131.88K | -58.77K | -49.05K | 224.81K | -52.85K | -63.96K | 6.87K | 98.53K | 206.94K | 271.54K | 263.37K | 133.05K | 56.42K | 1.15M | 948.24K | 26.04K | 62.51K | -97.13K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -5.77M | -2.49M | -69.00K | -1.03M | -1.27M | -1.86M | -438.00K | 758.32K | 2.06M | -255.45K | 205.26K | 192.15K | -696.68K | -683.41K | -428.50K | -960.65K | 1.14M | 1.03M | 1.07M | 177.19K | 716.38K | 1.48M | 697.00K | 475.89K | 517.84K | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -33.02% | -13.39% | -0.36% | -6.73% | -9.24% | -16.93% | -4.20% | 7.95% | 20.17% | -3.36% | 3.42% | 3.57% | -13.63% | -15.58% | -9.50% | -20.73% | 18.84% | 21.54% | 21.49% | 4.79% | 21.34% | 23.95% | 10.44% | 8.44% | 10.55% | 0.00% | 0.00% | 0.00% | 0.00% | -4.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.63K | 8.00K | 9.00K | -10.00K | 28.00K | 462.00K | -270.00K | 249.87K | 850.31K | -88.29K | 87.87K | 102.64K | -287.17K | -298.73K | -212.01K | -492.10K | 481.51K | 386.91K | 363.31K | 33.67K | 305.16K | 595.15K | 277.00K | -1.75M | 64.13K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 0.00 | -100.00K | 0.00 | 100.00K | 100.00K |
| Net Income | -5.77M | -2.49M | -78.00K | -1.02M | -1.30M | -2.32M | -168.00K | 508.45K | 1.21M | -167.16K | 117.40K | 89.51K | -409.51K | -384.68K | -216.49K | -468.56K | 662.14K | 647.14K | 707.78K | 143.52K | 411.22K | 886.24K | 420.00K | 2.22M | 550.84K | -100.00K | 300.00K | -100.00K | 0.00 | -100.00K | 0.00 | -200.00K | -1.40M | -600.00K | -1.00M |
| Net Income Ratio | -33.05% | -13.43% | -0.41% | -6.66% | -9.44% | -21.14% | -1.61% | 5.33% | 11.86% | -2.20% | 1.95% | 1.66% | -8.01% | -8.77% | -4.80% | -10.11% | 10.91% | 13.48% | 14.20% | 3.88% | 12.25% | 14.33% | 6.29% | 39.43% | 11.22% | -2.22% | 6.52% | -2.27% | 0.00% | -2.27% | 0.00% | -6.45% | -63.64% | -20.00% | -35.71% |
| EPS | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.40 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.23 | 0.22 | 0.25 | 0.05 | 0.15 | 0.32 | 0.15 | 0.84 | 0.23 | -0.04 | 0.11 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| EPS Diluted | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.38 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.22 | 0.21 | 0.24 | 0.05 | 0.15 | 0.32 | 0.15 | 0.79 | 0.22 | -0.04 | 0.10 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| Weighted Avg Shares Out | 7.70M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.23M | 3.04M | 3.03M | 3.02M | 3.02M | 2.98M | 2.97M | 2.96M | 2.89M | 2.90M | 2.89M | 2.82M | 2.76M | 2.74M | 2.77M | 2.80M | 2.63M | 2.43M | 2.43M | 2.73M | 2.73M | 2.29M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
| Weighted Avg Shares Out (Dil) | 7.75M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.34M | 3.17M | 3.03M | 3.09M | 3.11M | 2.98M | 2.97M | 2.96M | 2.89M | 3.03M | 3.05M | 3.00M | 2.97M | 2.82M | 2.77M | 2.80M | 2.82M | 2.52M | 2.43M | 3.00M | 2.73M | 2.50M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV...
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...
24 Stocks Moving in Wednesday's Pre-Market Session
Gainers Viveve Medical, Inc (NASDAQ: VIVE) shares rose 22.8% to $1.67 in pre-market trading after climbing 15.25% on Tuesday. Shotspotter Inc (NASDAQ: SSTI) shares rose 20.1% to...
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
Here's a roundup of top developments in the … Full story available on Benzinga.com
The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to look forward to for the unfolding week:...
The Wuhan Coronavirus: 21 Stocks to Watch
News like the Coronavirus can affect the stock market — either as a whole or just certain stocks and sectors. See how you can prepare.
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows...
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory submission for its recently approved...
Source: https://incomestatements.info
Category: Stock Reports